First treatment recommended for rare immunoglobulin-related autoimmune disease

View source ↗

Summary

The EMA recommended Uplizna (inebilizumab) as the first treatment for active IgG4-related disease, showing a reduction in disease flares in patients. This provi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Uplizna (inebilizumab)

Snippet

Uplizna significantly reduced the number of flares in patients with active immunoglobulin G4-related disease